Stock WANBURY WANBURY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Wanbury Limited NSE India S.E.

Equities

WANBURY

INE107F01022

Pharmaceuticals

Market Closed - NSE India S.E.
Other stock markets
 05:13:54 31/05/2024 pm IST 		5-day change 1st Jan Change
149.3 INR +0.50% Intraday chart for Wanbury Limited +1.22% +18.45%
01/04 Wanbury Limited Announces Retirement of Narinder Kumar Puri as Independent Director CI
21/02 Wanbury Limited Announces Retirement of Pallavi Prakash Shedge as Independent Director CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 735.3 518.3 454.5 2,075 2,777 1,221
Enterprise Value (EV) 1 3,228 3,101 2,124 3,745 3,360 1,984
P/E ratio -2.3 x -2.08 x 0.68 x -16.5 x 3.37 x -11.7 x
Yield - - - - - -
Capitalization / Revenue 0.2 x 0.13 x 0.12 x 0.53 x 0.54 x 0.24 x
EV / Revenue 0.87 x 0.79 x 0.58 x 0.95 x 0.66 x 0.4 x
EV / EBITDA -4.79 x 19.4 x 9.12 x 18.3 x 9.72 x 9.27 x
EV / FCF -49 x -39.3 x 2.25 x 32.6 x -13.1 x -12.8 x
FCF Yield -2.04% -2.54% 44.5% 3.07% -7.62% -7.79%
Price to Book -0.4 x -0.25 x -0.32 x -1.33 x -11.9 x -3.72 x
Nbr of stocks (in thousands) 23,720 23,720 24,970 25,015 32,665 32,705
Reference price 2 31.00 21.85 18.20 82.95 85.00 37.32
Announcement Date 14/09/18 09/09/19 03/09/20 03/09/21 06/09/22 05/09/23
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 3,717 3,914 3,675 3,925 5,112 4,996
EBITDA 1 -674.4 159.5 232.8 204.3 345.7 214.1
EBIT 1 -775.4 61.9 138.7 112.1 252.7 118.6
Operating Margin -20.86% 1.58% 3.78% 2.86% 4.94% 2.37%
Earnings before Tax (EBT) 1 -323.9 -249.8 646.7 -124.1 811.3 -102.9
Net income 1 -320.1 -248.5 644.6 -126.1 814.7 -104
Net margin -8.61% -6.35% 17.54% -3.21% 15.94% -2.08%
EPS 2 -13.49 -10.48 26.90 -5.041 25.21 -3.180
Free Cash Flow 1 -65.95 -78.85 945 115 -256.1 -154.6
FCF margin -1.77% -2.01% 25.72% 2.93% -5.01% -3.09%
FCF Conversion (EBITDA) - - 405.97% 56.28% - -
FCF Conversion (Net income) - - 146.6% - - -
Dividend per Share - - - - - -
Announcement Date 14/09/18 09/09/19 03/09/20 03/09/21 06/09/22 05/09/23
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net Debt 1 2,493 2,583 1,669 1,670 583 764
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -3.697 x 16.2 x 7.172 x 8.175 x 1.688 x 3.568 x
Free Cash Flow 1 -65.9 -78.8 945 115 -256 -155
ROE (net income / shareholders' equity) 22.5% 14.6% -43.1% 10.2% -129% 714%
ROA (Net income/ Total Assets) -14.2% 1.38% 3.07% 2.47% 4.92% 2.26%
Assets 1 2,258 -17,946 20,991 -5,109 16,551 -4,603
Book Value Per Share 2 -77.90 -88.20 -57.40 -62.50 -7.170 -10.00
Cash Flow per Share 2 1.210 1.160 1.060 4.000 6.900 0.4600
Capex 1 28.4 47.2 78.3 44.3 96.6 126
Capex / Sales 0.77% 1.2% 2.13% 1.13% 1.89% 2.53%
Announcement Date 14/09/18 09/09/19 03/09/20 03/09/21 06/09/22 05/09/23
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+15.91% 41.97B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.40% 22.34B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.48% 15.25B
CIPLA LIMITED Stock Cipla Limited
+16.12% 14B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+45.12% 12.06B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.58% 6.8B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.18% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. WANBURY Stock
  4. WANBURY Stock
  5. Financials Wanbury Limited